The US Food and Drug Administration (FDA) published the internal checklists its staff reference when reviewing drug and biologics applications to determine whether the submission is complete, or ...
The Food and Drug Administration (FDA) development and approval process for drugs and medical devices involves multiple phases that ensure the safety and effectiveness of products before and after ...
WASHINGTON, D.C. — The U.S. Food and Drug Administration announced two major actions last week: making its internal drug application checklists public to improve transparency and issuing the ...
The US Food and Drug Agency announced on March 9 new guidelines for testing biosimilar products, biologic drugs that are made by someone other than the inventor. Whereas a generic-drug manufacturer ...
FDA filing covers renewal applications for VLN® King and VLN® Menthol King, the first combusted cigarettes authorized as Modified Risk Tobacco Products, as 22nd Century advances its regulatory pathway ...
Sesh Products US, Inc. (Sesh) today announced that the U.S. Food and Drug Administration (FDA) has determined that its bundled Premarket Tobacco Product Application (PMTA) submission, covering 64 SKUs ...
Sanofi SNY announced that the FDA has extended the target action date for its new drug application (NDA) for tolebrutinib by three months. The NDA is seeking approval of tolebrutinib, an oral and ...
The Food and Drug Administration (FDA) has issued a Refuse-to-File (RTF) letter to Moderna, Inc. regarding its Biologics License Application (BLA) for the investigational mRNA-based influenza vaccine ...
The sNDA filing acceptance initiates substantive FDA review for Ameluz PDT in sBCC, with a target action date of Sept. 28, 2026 and no identified filing deficiencies. Approval would establish the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results